Pierre Paris

Pierre Paris

Auto-generated profile, based on publicly available information

Pierre Paris

CRCI2NA, Nantes Université, Université d’Angers, Inserm UMR 1307, CNRS UMR 6075, F-44000 Nantes, 49000 Angers, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PTPauline Thomas
Pauline Thomas
PPPierre Paris
Pierre Paris
CPClaire Pecqueur
Claire Pecqueur
Immunotherapy has emerged as a promising approach in the field of cancer treatment, with chimeric antigen receptor (CAR) T-cell therapy demonstrating remarkable success. However, challenges such as tumor antigen heterogeneity, immune evasion, and the limited persistence of CAR-T cells have prompted the exploration of alternative cell types for CAR-based strategies. Gamma delta T cells, a unique subset of lymphocytes with inherent tumor recognition capabilities and versatile immune functions, have garnered increasing attention in recent years. In this review, we present how arming Vδ2-T cells might be the basis for next-generation immunotherapies against solid tumors. Following a comprehensive overview of γδ T-cell biology and innovative CAR engineering strategies, we discuss the clinical potential of Vδ2 CAR-T cells in overcoming the current limitations of immunotherapy in solid tumors. Although the applications of Vδ2 CAR-T cells in cancer research are relatively in their infancy and many challenges are yet to be identified, Vδ2 CAR-T cells represent a promising breakthrough in cancer immunotherapy.

21 May 2026 in bioRxiv
Verified
Preprint
Open access
PPP. Paris
P. Paris
MDM. Devinat
M. Devinat
JCJ. Ceroni
J. Ceroni
EGE. Guiet
E. Guiet
JOJocelyn Ollier
Jocelyn Ollier
CPClaire Pecqueur
Claire Pecqueur
Glioblastoma (GBM) is characterized by a high degree of cellular plasticity and intra-tumoral heterogeneity, which frequently leads to the failure of standard therapies, including immunotherapies. While chimeric antigen receptor (CAR) T cells offer a potent means of MHC-independent tumor recognition, their efficacy is hampered by the coexistence of distinct molecular states, gathered as proneural (PN) and mesenchymal (MES) phenotypes. Here, we demonstrate that gangliosides GD2 and O-acetylated GD2 (OAcGD2) are preferentially expressed by PN cells whereas MES cells display reduced expression due to upregulated ganglioside catabolism. Conversely, MES cells are known to exhibit high expression of stress-induced ligands recognized by Vγ9Vδ2 T cells. We show that while engineering Vδ2T cells with GD2- or OAcGD2-specific CAR enables the elimination of PN cells, it also facilitates the immune escape of MES cells in heterogeneous 3D-tumoroid models. Mechanistically, we reveal a hierarchy of receptor engagement, where CAR signaling predominates leading to the structural and functional exclusion of endogenous TCR from the immunological synapse. To address this receptor competition, we propose a strategy that leverages the functional effector diversity by combining untransduced and CAR-engineered Vδ2T cells. This dual approach provides a dynamic safety net by ensuring the simultaneous elimination of PN and MES cells and preventing the selective outgrowth of resistant cells. Our findings establish a conceptual framework for designing off-the-shelf immunotherapies tailored to the metabolic and phenotypic plasticity of resistant solid tumors.

8 April 2026
Verified
Thesis
Closed access
PPPierre Paris
Pierre Paris
La thérapie cellulaire utilisant des lymphocytes T (LT) modifiés pour exprimer un récepteur chimérique à l’antigène (CAR) est l’une des stratégies les plus prometteuses en immunothérapie anticancéreuse. Validée dans les tumeurs hématologiques, elle reste encore peu efficace dans la plupart des tumeurs solides telle que le glioblastome (GBM). Une raison importante à cet échec est la forte hétérogénéité intra tumorale classiquement retrouvée dans ce cancer. Grâce à des études de transcriptomique, on peut distinguer ainsi des cellules mésenchymateuses (MES), classique et proneurale (CPN). Les LT Vδ2 présentent une réactivité innée contre les cellules MES, tandis que les cellules CPN expriment davantage le GD2 et le GD2 O- acétylé (OAcGD2). Ces deux antigènes sont des gangliosides associés à des contextes tumoraux. Un CAR ciblant l’un ou l’autre de ces gangliosides a ainsi été ajouté aux LT Vδ2 dans le but d’étendre leur réactivité aux cellules CPN. A l’aide d’essais d’activation et de lyse cellulaire in vitro, nous montrons ici que les LT Vδ2 CAR-GD2 et CAR-OAcGD2 permettent effectivement un ciblage des deux sous-types de GBM. Les deux LT Vδ2 CAR semblent cependant montrer une préférence pour la cible du CAR dans les essais contre des modèles mélangeant les deux sous-types. De plus, seuls les LT Vδ2 CAR-GD2 améliorent la survie des souris dans les modèles in vivo testés. Cette approche nécessite désormais d’être raffinée pour augmenter l’efficacité des LT Vδ2 CAR afin d’avoir les bases nécessaires avant de pouvoir étudier leurs effets dans le cadre d’études cliniques.